Find News

Filter articles

Applied Filters

Showing 1 to 10 of 845 results

LSIPR, Gowling WLG team up for biologics survey

International22-06-2021Alex Baldwin

Life Sciences IP Review has partnered with international law firm Gowling WLG to launch the Patent Litigation Survey to appraise the patent trends in biologics, biosimilars and next generation therapies.

Japan’s IP office upholds CRISPR patent and allows third

Japan01-06-2021Muireann Bolger

A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.

SCOTUS declines patents review on Enbrel drug

US18-05-2021Muireann Bolger

A Novartis unit, Sandoz, has failed to persuade the US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug Enbrel (etanercept).

WHO urges vigilance against fake COVID-19 vaccines

29-03-2021Rory O'Neill

The World Health Organization has warned the public of the danger of counterfeit COVID-19 vaccines and urged people not to procure jabs outside of government channels.

Pyxis secures ADC licence from Pfizer

US22-03-2021Rory O'Neill

Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.

Medical tech leads 2020 innovation at the EPO

EU16-03-2021Muireann Bolger

Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed.

China must protect seed IP to spur investment, warns Sinochem

China11-03-2021Muireann Bolger

China must safeguard IP in the seed industry to ensure innovation within the sector, the group chairman of Chinese multinational Sinochem, Frank Ning, has warned.

Five minutes with… Penny Gilbert


The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

A deep dive into Regeneron v Kymab

US08-03-2021Alex Baldwin

On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.

Puma and CANBridge cancel licensing deal for $20m

International02-03-2021Rory O'Neill

Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China.

Showing 1 to 10 of 845 results